Publication: BR34

The CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer study results were recently published in the Journal of Thoracic Oncology.

More >>
 
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
 
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
 
Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).

More >>
 

Planned trials

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

MEC6

Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma

PAC4

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

More >>

Recently activated

CLC3

Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)

More >>

I240

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

More >>

I240A

A Study of Durvalumab and BA3011 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

More >>

I240B

A Study of Durvalumab and BA3021 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

More >>

MAC28

De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

New pancreatic cancer trial provides hope to BC family

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (ONLINE)

J Clin Oncol , 2022
Mayer EL;Fesl C;Hlauschek D;Garcia-Estevez L;Burstein HJ;Zdenkowski N;Wette V;Miller KD;Balic M;Mayer IA;Cameron D;Winer EP;Ponce Lorenzo JJ;Lake D;Pristauz-Telsnigg G;Haddad TC;Shepherd L;Iwata H;Goetz M;Cardoso F;Traina TA;Sabanathan D;Breitenstein U;Ackerl K;Metzger Filho O;Zehetner K;Solomon K;El-Abed S;Theall KP;Lu DR;Dueck A;Gnant M;DeMichele A;

More >>

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) (ONLINE)

J Clin Oncol , 2022
Khan SA;Zhao F;Goldstein LJ;Cella D;Basik M;Golshan M;Julian TB;Pockaj BA;Lee CA;Razaq W;Sparano JA;Babiera GV;Dy IA;Jain S;Silverman P;Fisher CS;Tevaarwerk AJ;Wagner LI;Sledge GW;

More >>

Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance) (ONLINE)

J Clin Oncol , 2022
Cheng E;Ou FS;Ma C;Spiegelman D;Zhang S;Zhou X;Bainter TM;Saltz LB;Niedzwiecki D;Mayer RJ;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Brown JC;Ng K;Gross CP;Meyerhardt JA;Fuchs CS;

More >>

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer

Ann Oncol 33: 42 - 56, 2022
Federico L;McGrail DJ;Bentebibel SE;Haymaker C;Ravelli A;Forget MA;Karpinets T;Jiang P;Reuben A;Negrao MV;Li J;Khairullah R;Zhang J;Weissferdt A;Vaporciyan AA;Antonoff MB;Walsh G;Lin SY;Futreal A;Wistuba I;Roth J;Byers LA;Gaudreau PO;Uraoka N;Cruz AF;Dejima H;Lazcano RN;Solis LM;Parra ER;Lee JJ;Swisher S;Cascone T;Heymach JV;Zhang J;Sepesi B;Gibbons DL;Bernatchez C;

More >>

Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens

Int J Cancer 150: 279 - 289, 2022
Quintanilha JCF;Wang J;Sibley AB;Xu W;Espin-Garcia O;Jiang C;Etheridge AS;Ratain MJ;Lenz HJ;Bertagnolli M;Kindler HL;Dickler MN;Venook A;Liu G;Owzar K;Lin D;Innocenti F;

More >>

Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

Pharmacogenetics and Genomics 31: 215 - 220, 2021
Patel JN;Jiang C;Owzar K;Mulkey F;Luzum JA;Mamon HJ;Haller DG;Dragovich T;Alberts SR;Bjarnason G;Willet CG;Niedzwiecki D;Enzinger P;Ratain MJ;Fuchs C;McLeod HL;

More >>

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Clinical Lymphoma Myeloma and Leukemia 21: 766 - 774, 2021
Cheung MC;Mittmann N;Owen C;bdel-Samad N;Fraser GAM;Lam S;Crump M;Sperlich C;van der Jagt R;Prica A;Couban S;Woyach JA;Ruppert AS;Booth AM;Mandrekar SJ;McDonald G;Shepherd LE;Yen H;Chen BE;Hay AE;

More >>